Science & Nature
- NEWS FEATURE
Private biotech financing in 2023 is more discriminate, disciplined and demanding. Strong data and efficiency are de rigueur.
Melanie Senior
London, UK.
The 2020s have flung biotech from the heights of pandemic exuberance, when cash grew on trees and anyone with a lab coat could take a company public, to the belt-tightening lows of 2022, with layoffs, liquidations and falling valuations.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41587-023-00001-z
Read More
Melanie Senior